Pre-Made Lerodalcibep Biosimilar, Fusion Protein targeting PCSK9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 for drug discovery and mechanism of action (MOA) research

Pre-Made Lerodalcibep Biosimilar, Fusion Protein targeting PCSK9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lerodalcibep is a recombinant fusion protein of a proprotein convertase subtilsin-kexin type 9 (PCSK9)-binding domain (adnectin) and human serum albumin (HAS). Binding of adnectin to PCSK9 prevents the interaction between PCSK9 and the LDL receptor. Linkage of HAS to the adnectin increases the half-life of 12 to 15 days. PCSK9 inhibitors are a new class of drugs that lower LDL, or ¡°bad,¡± cholesterol. These agents target and inactivate proprotein convertase subtilsin-kexin type 9 (PCSK9), a hepatic protease that attaches and internalizes LDL receptors into lysosomes hence promoting their destruction.